Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.

The investment firm supplied $50m for telehealth platform developer MDLive, which already counts Sentara, Cigna, Sutter Health, Novo and HCSC as investors.

The Johns Hopkins spinout has raised cash from OUP as it looks to move its first candidate, targeting skin itch complications, into the clinic.

China Life has returned for a $142m series D-plus round for cancer treatment developer Biocytogen, having already co-led its $77m series D round 13 months ago.

Mission Bay Capital has placed a bet on Symbiome, creators of a skin care range intended to emulate our ancestor’s microbiome.

Cordovan Capital Partners has sold its stake in QUB-founded clinician training equipment supplier TruCorp at a 10.4-fold return.

Baxter International scored an exit as dialysis machine developer Outset Medical floated above its range in an upsized offering.

Syncona has equipped Resolution with funding to explore a restorative liver therapy based on the research of Edinburgh's Prof Stuart Forbes.

Syncona, Jeito Capital and EcoR1 Capital have co-led the Netherlands Cancer Institute-founded Neogene Therapeutics' series A round.

Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.